Browse

We’re getting our first signs of where healthcare costs are heading next year. According to a survey of actuaries at 27 health plans covering employers and individuals on the exchanges

The developer of a leading PD-1/VEGF cancer drug cited “market conditions” for the cancellation. Its shares have struggled to break out following data milestones.

DHL is in discussions with multiple major drugmakers who are looking for the logistics company to either take over their sites or access its resources, the company’s supply chain business CEO Hendr…